Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts (NYSE:PFE)

Pfizer Inc. (NYSE: PFE ) gave us strong 2Q25 figures. We saw double-digit revenue growth, margin expansion, and rising earnings. Mainly driven by key products like Comirnaty, Paxlovid, and Vyndaqel. However, the big news this quarter is, of course, theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific fo ...